Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Cerebral and Cardiac Blood Flow During Exercise in Patients With COPD (REFLEX-COPD)

28 octobre 2019 mis à jour par: University of Nottingham

Cardiac Output and Brain Perfusion and Architecture During Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Healthy, Age Matched Volunteers

Heart disease and conditions related to the blood vessels are responsible for a large proportion (over a quarter) of the deaths in people with chronic obstructive pulmonary disease (COPD). The changes can also affect the smaller smaller blood vessels within the body, in particular the brain and the kidneys. This might be related to how the heart pumps and if it is under any pressure. Investigations performed at the University in healthy older volunteers demonstrated how the blood flows in the brain and heart during exercise. Exercise gently puts the whole body under some pressure and therefore exposes any weaker areas.

In this study the investigators are hoping to find out what happens to the blood flow in the brain and in the heart in patients who have COPD when they exercise and in the resting state. This will be compared to people of a similar age with a similar smoking history but without COPD. This will be examined using state of the art magnetic resonance imaging (MRI) and will allow us to assess whether changes in structure and function are related to this altered blood flow.

Our hypothesis is that COPD will cause a larger change in blood flow during exercise compared to the healthy volunteers and that reduced cardiorespiratory fitness will be associated with increased age related structural within the brain.

Aperçu de l'étude

Statut

Inconnue

Les conditions

Description détaillée

The aim is to recruit 20 participants with COPD, who will be compared to 10 age and gender matched controls who also have a smoking history. The investigators aim for this number to complete the components of the study and therefore may have to over-recruit if some people drop out or are not eligible. The study elements are feasible, as the work extends a previous research study in healthy volunteers.

This research trial will consist of a medical screening visit and three investigation study visits spaced ideally one week apart. The investigation visits will begin within 6 (ideally within 4) weeks of the medical screening visit. The total duration of the study and screening visits should be 12 weeks maximum for each participant.

Screening visit:

If the participant expresses an interest in the clinical trial and wants to take part they will be invited (at a convenient time for them) to attend a medical screening visit located at the Nottingham City hospital. Here the investigator will discuss the research trial and answer any questions or concerns they might have regarding the research trial. The participant, if willing, will then be required to sign a consent form so that the screening procedures can begin, which include:

  • Blood sample: Approximately a 20ml sample (4 teaspoons) taken from their arm, for further investigation including full blood count (FBC), brain natriuretic peptide (BNP) and kidney function.
  • Questionnaires: 5 different questionnaires that ask about symptoms and how they affect daily life, a physical activity questionnaire, quality of life questionnaire and a MRI safety questionnaire.
  • Spirometry: A simple blowing test to assess the participants' breathing which is performed three times.
  • 12 lead ECG.
  • a hand grip dynamometer to assess muscle strength
  • timed up and go test: a test used to measure gait speed, where participants are asked to get up from a chair and walking to 3 meters and back, whilst being timed.
  • to wear a step counter (Sensewear armband) for a week during waking hours to record steps.

Provided the ECG, step count (<10,000 steps) and other screening elements are ok, the participant will proceed to Study visit 1.

Strength and exercise test protocol:

The participant will be required to abstain from strenuous exercise for the 48 hours prior to the visit and also from alcohol and caffeine for 24 hours prior. Upon arrival they will perform a knee extension exercise so we can establish the muscle strength in the legs, specifically 3 maximal knee extensions with a 30 second rest in between. We will also measure fatigue by dong 20 extensions after a short break.

After a break they will then undergo an exercise test using an MRI compatible stepper device (Ergospect Cardiostepper) whilst in a supine position. This has been adapted to be similar to how they will exercise in the MRI scanner. Volunteers will start off stepping at a frequency of 65-70 steps a minute at the minimum workload and every 3 minutes get gradually a little harder until exhaustion is reached. Heart rate at rest and in response to exercise will be measured using a heart monitor. Participants will be given the option to have their expired gases also measured during exercise using a face mask, though this is not necessary if not tolerated. In the final minute of each workload we will take a finger prick test to measure the gases in the patients blood. A 3 lead ECG and oxygen saturation probe will be attached during exercise as safety measures and the protocol will be halted if oxygen saturation falls below 80% or if any relevant rhythm abnormalities are seen on the ECG trace.

The second study visit will be used to confirm the exercise and strength parameters measured in the first study visit.

MRI protocol:

A series of scans of the brain and heart will be taken at rest and then whilst stepping on the stepper machine within the MRI. The exercise will be at a steady state low level intensity determined by calculating the workload at which a fraction of maximum heart rate was achieved during first 2 study visits.

The MRI scan itself will take about ¾ hour but upto 2 hours is allowed for preparation and introducing the scan to the participant. The scanner is quite noisy and so the participant will wear ear defenders during the scan. Because the scanner is built around a large magnet, the participant will be instructed to remove all metal from their body, including jewellery. There is no radiation involved.

Type d'étude

Observationnel

Inscription (Anticipé)

30

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Nottinghamshire
      • Nottingham, Nottinghamshire, Royaume-Uni, NG5 1PB
        • Recrutement
        • NIHR Nottingham BRC Respiratory Theme, University of Nottingham and NUH Trust
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

60 ans à 75 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon de probabilité

Population étudiée

We are recruiting participants within the Nottinghamshire region. Specifically for patients with COPD, we are targeting outpatient respiratory clinics at the Nottingham University Hospitals Trust, inpatient admissions due to COPD exacerbation at the Nottingham City Hospital, pulmonary rehabilitation groups and respiratory focus groups within Nottingham and patients on the Nottingham Respiratory Research Unit database.

La description

Inclusion Criteria:

  • Patients aged 65-75 years old,
  • >10 pack years smoking,
  • FEV1/FVC <0.7 and FEV1<60% predicted (for COPD participants only)
  • Sedentary lifestyle (<10,000 steps per day)
  • Able to give informed consent
  • Able to read, understand and communicate coherently in English

Exclusion Criteria:

  • Doctor diagnosis of ischaemic heart disease or heart failure
  • Doctor diagnosis of dementia or Alzheimers disease
  • History of previous cerebrovascular disease (stroke or TIA) or malignancy
  • Pregnancy or childbearing in the last 6 months
  • Maintenance oral corticosteroids in the past 6 months
  • Requirement for oral corticosteroids or antibiotics in the past 6 weeks
  • Active arthritis or other muscular condition limiting exercise
  • Surgical intervention in the last 12 weeks
  • Long term oxygen therapy requirement
  • Other formal current respiratory diagnosis
  • Thyroid disease
  • Diabetes Mellitus
  • Neurological or cognitive impairment
  • Significant physical disability
  • Any other conditions in addition to the above that the investigators consider may affect study measurements or safety
  • Inability to understand verbal and/or written explanation of the study requirements

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: Cas-témoins
  • Perspectives temporelles: Transversale

Cohortes et interventions

Groupe / Cohorte
Case
Participants with a pack year history of more than 10 pack years, diagnosed with COPD who have FEV1/FVC ratio of less than 0.7 AND FEV1 predicted value less than or equal to 60%.
Control
Participants without a diagnosis of COPD who have a smoking history of more than 10 pack years

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Resting white and grey matter structural integrity
Délai: up to 12 weeks
Grey and white matter volume (mm3) using the MRI MPRAGE sequences will be measured at rest
up to 12 weeks
Cardiac structural integrity
Délai: up to 12 weeks
Cardiac output (L/min) will be measured using the MRI sequence (Short axis Cine) at rest.
up to 12 weeks
Cardiac structural integrity
Délai: up to 12 weeks
Cardiac fibrosis (%) will be measured using the MRI MOLLI T1 sequence at rest.
up to 12 weeks
Cardiac structural integrity
Délai: up to 12 weeks
Myocardial strain (%) will be measured using the MRI cardiac tagging sequence at rest.
up to 12 weeks
Whole body fat and muscle quantification
Délai: up to 12 weeks
Whole body fat and muscle quantification (%) will be measured using the MRI whole body mdixon sequence at rest.
up to 12 weeks
Aortic flow
Délai: up to 12 weeks
Aortic flow (ml/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Cerebral blood flow
Délai: up to 12 weeks
Cerebral blood flow (ml/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Cerebral perfusion
Délai: up to 12 weeks
Cerebral artery perfusion (ml/100g/min) will be measured during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks
Oxygen extraction fraction
Délai: up to 12 weeks
Oxygen extraction fraction (%) will be derived from the difference between arterial and venous cerebral oxygenation measured via TRUST MRI scan sequence during rest, low level steady-state exercise and following cessation of exercise and compared between COPD and age and gender matched controls
up to 12 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Muscle isometric strength (MVC)
Délai: up to 6 weeks
Isometric muscle torque of the quadriceps (Nm) assessed using the cybex dynamometer
up to 6 weeks
Muscle isokinetic fatigue
Délai: up to 6 weeks
Fatiguability test of the quadriceps (Nm) assessed using the cybex dynamometer
up to 6 weeks
Quality of life (SGRQ)
Délai: 1 week
Assessed using the St Georges Respiratory Questionnaire. min value: 0, max value: 84, higher score means worse outcome
1 week
Physical activity level (IPAQ Physical activity questionnaire)
Délai: 1 week
Assessed using the International Physical activity questionnaire. min value: 0, max value: 66000, higher score means better outcome
1 week
Montreal Cognitive Assessment (MoCA) cognition level
Délai: 1 week
Assessed using the Montreal cognitive assessment questionnaire. min value: 0, max value: 30, higher score means better outcome
1 week
Hospital anxiety and depression scale (HADS)
Délai: 1 week
min value: 0, max value: 21, higher score means worse outcome
1 week
Hand grip strength
Délai: 1 week
Composite of hand grip strength (Kg), measured by a hand held dynamometer,
1 week
Timed up and go test
Délai: 1 week
Timed up and go test (seconds) will be measured to assess degree of frailty.
1 week
Serum markers of inflammation for research purposes (likely to include IL-1, IL-6, and TNFα)
Délai: 1 week
Blood test
1 week
Heart rate response to exercise
Délai: up to 6 weeks
Heart rate response (Beats per minute) will be measured at rest and during incremental exercise to assess cardio-respiratory fitness.
up to 6 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Charlotte Bolton, NIHR Nottingham Biomedical Research Centre Respiratory theme, University of Nottingham

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

3 janvier 2019

Achèvement primaire (Anticipé)

30 septembre 2020

Achèvement de l'étude (Anticipé)

30 septembre 2020

Dates d'inscription aux études

Première soumission

17 octobre 2019

Première soumission répondant aux critères de contrôle qualité

22 octobre 2019

Première publication (Réel)

24 octobre 2019

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

30 octobre 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 octobre 2019

Dernière vérification

1 octobre 2019

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

Indécis

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner